HHS has sent drug for Ebola clinical trial
-
By
-
Theresa Gaffney
-
Helen Branswell
-
June 23, 2026
-
Clinical Scorecard: HHS has dispatched medication for Ebola clinical research trial
At a Glance
| Category | Detail |
|---|
| Condition | Ebola Virus Disease |
| Key Mechanisms | Monoclonal antibody therapy (MBP-134) |
| Target Population | Individuals exposed to or infected with Ebola |
| Care Setting | Clinical trial settings in the Democratic Republic of the Congo and Uganda |
Key Highlights
- HHS sent doses of monoclonal antibody MBP-134 for clinical trials.
- The monoclonal has completed a Phase 1 safety trial.
- The WHO is reviewing the trial protocol with ethics committees.
- Confirmed Ebola cases in the DRC have reached 1,048 with 267 deaths.
Guideline-Based Recommendations
Diagnosis
- Confirm Ebola virus infection through laboratory testing.
Management
- Utilize monoclonal antibody therapy as part of treatment protocols.
Monitoring & Follow-up
- Monitor patients for adverse effects and treatment efficacy.
Risks
- Potential for severe disease progression and mortality.
Patient & Prescribing Data
Patients at risk of or diagnosed with Ebola virus infection.
MBP-134 is a promising treatment option under investigation.
Clinical Best Practices
- Follow ethical guidelines for clinical trials.
- Ensure informed consent from participants.
- Implement rigorous monitoring of trial outcomes.
Related Resources & Content
